Tom Wilemon

Sam S. Chang, MD, MBA
December 14, 2023

Sam S. Chang recognized by the American Urological Association

The American Urological Association has announced that Vanderbilt’s Sam S. Chang, MD, MBA, is one of its 2024 award recipients.

By Tom Wilemon
The visit was the first time a group of Ukrainian oncologists came to VUMC to learn about cancer research and care.
November 30, 2023

Ukrainian oncologists visit Vanderbilt-Ingram Cancer Center

A group of Ukrainian oncologists recently visited Vanderbilt-Ingram Cancer Center where they toured research labs, observed tumor board meetings, met with several Vanderbilt oncologists, and attended the 23rd Annual Retreat for Cancer Biology.

By Tom Wilemon
October 26, 2023

Debra Friedman named deputy director of Vanderbilt-Ingram Cancer Center

Internationally recognized cancer survivorship expert Debra Friedman, MD, MS, has been named deputy director of Vanderbilt-Ingram Cancer Center

By Tom Wilemon
October 17, 2023

Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Vanderbilt-Ingram Cancer Center has earned a Merit Extension Award from the National Cancer Institute in recognition of more than a decade of sustained exceptional progress.

By Tom Wilemon
October 12, 2023

Prostate cancer survivors symposium set for Nov. 11

Vanderbilt University Medical Center Department of Urology and Vanderbilt-Ingram Cancer Center are hosting a symposium for prostate cancer survivors and their families on Saturday, Nov. 11.

By Tom Wilemon
x-ray of stomach
October 12, 2023

Symposium for patients, caregivers and family members offers important information on stomach cancer, Nov. 4

A Vanderbilt symposium on Nov. 4 offers detailed information for patients, caregivers and family members about stomach cancer.

By Tom Wilemon
October 5, 2023

Study validates pyrvinium as treatment to prevent stomach cancer

A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.
By Tom Wilemon
October 4, 2023

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.
By Tom Wilemon
September 12, 2023

Study finds new genetic susceptibilities for colon cancer

Vanderbilt researchers at have found new genes that put people at higher risk for colon cancer and rectal cancer. 
By Tom Wilemon
September 1, 2023

Foundation funds research to block drug resistance in cancer treatment

The Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation has funded an ambitious initiative to overcome one of the most perplexing and frustrating mysteries of cancer treatment — how to prevent drug resistance.
By Tom Wilemon
August 10, 2023

New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs.
By Tom Wilemon
August 8, 2023

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
By Tom Wilemon